查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466015

干细胞治疗市场：依类型、细胞来源、治疗应用、最终使用者、预测（2024-2030）

Stem Cell Therapy Market by Type, Cell Source, Therapeutic Application, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球干细胞治疗市场规模为4.3983亿美元，2024年达4.9323亿美元，2030年将达10.2744亿美元，复合年增长率为12.88%。

干细胞疗法是指在医学上利用干细胞来取代和修復受损的组织和器官。透过刺激身体的修復机制，这种治疗方法对于治疗多种疾病非常重要，包括帕金森氏症、阿兹海默症、糖尿病和心臟病。干细胞有潜力在生命的早期阶段和生长过程中产生体内各种类型的细胞。慢性病的流行和政府积极的再生治疗措施正在增加全世界对干细胞治疗的需求。然而，高成本、严格的监管以及围绕核准流程的担忧给主要企业带来了重大挑战。公司正试图透过遵守政府施加的严格标准来在这一领域保持敏捷。此外，再生医学领域的重大发展和持续的研发活动正在为主要企业未来的业务扩张做出贡献。

主要市场统计
基准年[2023] 4.3983亿美元
预计年份 [2024] 4.9323 亿美元
预测年份 [2030] 10.2744亿美元
复合年增长率（%） 12.88%

类型：在慢性病治疗中越来越多地使用同种异体和自体干细胞疗法

同种异体移植是一种将干细胞从捐赠者移植到另一个接受者的治疗方法。当患者的细胞不适合治疗时，例如遗传性疾病，这种治疗方法通常是首选。它还具有易于获得并允许快速治疗的优点。另一方面，自体干细胞疗法使用从患者的骨髓、脂肪组织或血液中提取的干细胞。这种类型的治疗方法免疫排斥的风险较低，因为细胞取自患者体内。

细胞来源：在组织重塑和组织修復中越来越多地采用 AD-MSC 和 BM-MSC

脂肪组织间质干细胞（AD-MSC）是从脂肪组织（通常称为体脂肪）中获得的。这些细胞引起了人们极大的兴趣，因为它们相对容易获得。 AD-MSC 的萃取比其他来源需要更少的侵入性操作，并且可以在局部麻醉下透过抽脂手术进行。 AD-MSC 可分化为多种细胞类型、分泌生长因子并调节免疫反应，因此可用于多种治疗方法。同时，从骨髓（通常是骨盆的髂嵴）中间质干细胞（BM-MSC）。 BM-MSC 是广泛研究的干细胞之一，已知具有分化成骨、软骨和脂肪组织的潜力。 BM-MSC 还具有强大的免疫调节特性，使其成为治疗自体免疫疾病和支持骨髓移植植入的有力候选者。另一方面，胎盘脐带间间质干细胞（PC-UC-MSC）是在出生后从胎盘和脐带中获得的。这些细胞可以非侵入性地收穫，并且与 AD-MSC 和 BM-MSC 等成体干细胞相比具有较高的增殖率。

治疗应用：再生医学在各个治疗领域日益普及

干细胞被认为是治疗各种心血管疾病（包括心肌梗塞和郁血性心臟衰竭）的突破性选择。基于干细胞的手术有可能再生受损的心臟组织、改善心臟功能并刺激心臟细胞修復。在狼疮和类风湿性关节炎等疾病中，硬化干细胞疗法可以改变疾病进程并恢復免疫平衡。这些细胞可以调节 T 细胞反应，并已用于治疗某些自体免疫疾病。干细胞疗法可望再生软骨、骨骼和肌肉组织，以治疗骨关节炎、肌肉萎缩症萎缩症和其他肌肉骨骼疾病。这种治疗方法旨在减轻疼痛、改善功能，并延迟或避免关节重建手术等侵入性治疗的需要。干细胞疗法治疗阿兹海默症神经系统疾病的潜力在于其保护、修復和取代神经细胞和神经胶质细胞的能力。干细胞已显示出促进伤口癒合的重要能力。透过在伤口护理中使用间质干细胞，这些细胞可以促进皮肤组织再生、减少疤痕并缩短癒合时间。这对于烧烫伤患者、糖尿病溃疡患者以及创伤治疗缓慢的患者尤其重要。

最终用户：学术研究中心和医院更多地使用干细胞疗法，以提供有效、安全和标准化的治疗结果

学术和研发中心对于推进干细胞科学至关重要，需要各种干细胞来推进疾病研究、药物开发和突破性治疗方法的开发。这些机构对开创性研究做出了重大贡献，并且是干细胞应用创新的温床。另一方面，门诊手术中心（ASC）为某些类型的门诊干细胞治疗提供了一个场所。这些中心比医院需要更少的资源，使它们成为患者和付款人的具有成本效益的选择。医院和诊所仍然是干细胞治疗的主要场所，特别是对于复杂和急性疾病。医院和诊所服务的患者的多样性推动了对各种干细胞治疗的需求，包括针对白血病和淋巴瘤等疾病的造血干细胞移植（HSCT）以及各种再生医学应用。生物製药公司在干细胞疗法的开发和商业化中发挥着重要作用。他们购买干细胞不仅用于研究和开发目的，例如发现新药和开发再生医学，而且还用于製造目的，利用干细胞株大规模生产治疗产品。生物製药公司对干细胞疗法的兴趣与其不断寻找比现有药物提供更好治疗效果的创新治疗方法是一致的。生物製药公司正在致力于干细胞疗法的开发和商业化。购买干细胞不仅用于研究和开发目的，例如发现新药和开发再生医学，而且还用于製造目的，其中干细胞株用于大规模生产治疗产品。

区域洞察

美国和加拿大等国家拥有发达的医疗保健基础设施和较高的慢性病发病率，增加了对干细胞疗法等创新治疗方法的需求。客户的购买行为反映了采用新医疗保健技术的强烈趋势，特别是在再生医学等领域。该地区在干细胞专利方面的领先地位支持了强大且不断发展的治疗市场，大量的研究投资和活动证明了这一点。欧盟（EU）为干细胞治疗提供了多元化的空间，德国、英国和法国等国家则专注于研究和临床应用。同时，由于在改善医疗保健方面的大量投资以及对先进医学的需求不断增加，中东和非洲对干细胞疗法的兴趣正在迅速增加。杜拜细胞治疗和再生医学框架等倡议旨在将该地区定位为干细胞治疗医疗旅游中心。同时，在亚洲，中国、日本和印度等国家的干细胞治疗市场迅速扩大，政府的支持性政策为研究和创新创造了蓬勃发展的环境。日本和中国拥有快速核准再生医学产品的先进法规，使这些国家成为采用干细胞疗法的主要空间。在印度，医疗保健基础设施正在改善，公共和私人研究经费正在增加，干细胞治疗的使用正在扩大，并且正在转向研究和开发。

FPNV定位矩阵

FPNV定位矩阵对于评估干细胞治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对干细胞治疗市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，以获得市场竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.干细胞治疗市场的市场规模与预测是多少？

2.干细胞治疗市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3. 干细胞治疗市场的技术趋势和法规结构是什么？

4.干细胞治疗市场主要厂商的市场占有率是多少？

5. 进入干细胞治疗市场的合适形式和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地退化性疾病和癌症的发生率正在上升
      • 世界各地政府围绕干细胞治疗的措施增加
      • 干细胞治疗中心和诊所扩建
    • 抑制因素
      • 实施干细胞治疗的困难
    • 机会
      • 干细胞治疗的持续进展
      • 干细胞疗法和治疗方法的销售和临床试验核准正在迅速增加
    • 任务
      • 干细胞治疗的伦理与安全问题
  • 市场区隔分析
    • 类型：在慢性病治疗中越来越多地使用同种异体和自体干细胞疗法
    • 细胞来源：在组织重塑和组织修復中越来越多地采用 AD-MSC 和 BM-MSC
    • 治疗应用：再生医学在各个治疗领域日益普及
    • 最终用户：学术研究中心和医院更多地使用干细胞疗法，以提供有效、安全和标准化的治疗结果
  • 市场趋势分析
    • 严格的基于干细胞治疗的研究倡议、不断发展的法规结构以及对先进治疗方法不断增长的需求正在推动美洲市场的发展
    • 亚太国家的政府资助和医疗旅游实践增加了干细胞疗法的采用，推动了干细胞疗法的进步
    • 由政府资助的学术机构和生物技术公司组成的强大网络加速了欧洲、中东和非洲的干细胞研究和商业化
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章干细胞治疗市场：依类型

  • 同种异体干细胞疗法
  • 自体干细胞治疗

第七章干细胞治疗市场：细胞来源

  • 脂肪组织来源的 MSC
  • 骨髓间质干细胞
  • 胎盘/脐带来源的 MSC

第八章干细胞治疗市场：依治疗应用分类

  • 心血管疾病手术
  • 发炎疾病/自体免疫疾病
  • 肌肉骨骼疾病
  • 神经系统疾病
  • 整形外科和风湿病学
  • 伤口和伤害

第九章干细胞治疗市场：依最终使用者分类

  • 学术研究中心
  • 门诊手术中心
  • 生技/製药公司
  • 医院/诊所

第十章美洲干细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太干细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲干细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • FUJIFILM投资2亿美元用于细胞疗法生产
    • FDA 拒绝后 Mesoblast 开始合作进行 SR-aGVHD 试验
    • Selecta Biosciences 宣布与 Cartesian Therapeutics 合併
    • Takara Bio 与 Fondazione Telethon ETS 签署 RetroNectin授权合约
    • 拜耳开设第一家细胞疗法製造工厂，推动全球再生医学发展
    • 诺和诺德基金会投资1.35亿美元建造细胞治疗工厂
    • BioLineRx 宣布 FDA核准APHEXDA（莫替沙福肽）与Filgrastim（G-CSF）联合用于多发性骨髓瘤患者的造血干细胞采集和随后的自体移植
    • BlueRock Therapeutics 和 bit.bio 宣布就基于调节性 T 细胞 (Treg) 的治疗治疗方法发现和製造达成合作和选择权协议
    • StemCyte与美国领先的免疫细胞治疗公司签署合作协议，为同种异体工程细胞疗法提供药物製造原料
    • CIRM 投资 8,900 万美元用于干细胞和基因治疗研究
    • 百时美施贵宝在美国开设新的病毒载体生产工厂，增强细胞治疗能力
    • 诺和诺德扩大在大都会圈的研发足迹
    • Garuda Therapeutics 获得 6,200 万美元 B 轮资金筹措，用于推进现成的血液干细胞技术平台
    • BioCardia 和 CellProthera 加强合作，开发 ProtheraCytes，用于治疗欧洲的急性心肌梗塞，并有可能为患者提供早期治疗机会
    • ReLive Biotechnologies Ltd. 完成对 Co.Don AG 资产的收购和 SHC主导的A 轮资金筹措，进一步实现成为全球再生疗法公司的雄心

第14章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-431752EA49AD

[195 Pages Report] The Stem Cell Therapy Market size was estimated at USD 439.83 million in 2023 and expected to reach USD 493.23 million in 2024, at a CAGR 12.88% to reach USD 1,027.44 million by 2030.

Stem cell therapy refers to the medical use of stem cells to replace and repair damaged or diseased tissue or organs. This therapy is important in treating various diseases, including Parkinson's, Alzheimer's, diabetes, and heart disease, by stimulating the body's repair mechanisms. Stem cells can potentially develop many different cell types in the body during early life and growth. The prevalence of chronic diseases and favorable government initiatives for regenerative treatments worldwide boost the need for stem cell therapy. However, the concerns associated with the high cost, stringent regulations, and approval processes are a significant challenge for the key players. Companies are trying to comply with the robust standards imposed by the governments to remain agile within the spaces. Moreover, the advancements in regenerative therapy and the continuous research and development activities in stem cell therapy contribute to the future expansion of key players.

KEY MARKET STATISTICS
Base Year [2023] USD 439.83 million
Estimated Year [2024] USD 493.23 million
Forecast Year [2030] USD 1,027.44 million
CAGR (%) 12.88%

Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments

Allogeneic stem cell therapy involves the transplantation of stem cells from a donor to another recipient. This therapy is often preferred in conditions for patients with cells unsuitable for therapy, such as in cases with genetic disorders. It also allows for off-the-shelf solutions, leading to rapidness in treatment administration. On the other hand, autologous stem cell therapy uses a patient's stem cells collected from their bone marrow, adipose tissue, and blood. This type of therapy is associated with a lower risk of immune rejection since the cells are derived from the patient's body.

Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing

Adipose tissue-derived mesenchymal stem cells (AD-MSCs) are obtained from adipose tissue, commonly known as body fat. These cells are of significant interest due to their relative ease of access. The extraction of AD-MSCs involves less invasive procedures than other sources and can be done under local anesthesia via liposuction. AD-MSCs are used in various therapeutic approaches because they differentiate into multiple cell types, secrete growth factors, and modulate immune responses. At the same time, bone marrow-derived mesenchymal stem cells (BM-MSCs) are harvested from the bone marrow, typically from the iliac crest of the pelvis. They are among the extensively studied stem cells with known potential to differentiate into bone, cartilage, and adipose tissue. BM-MSCs also have robust immunomodulatory properties, making them prominent candidates for treating autoimmune diseases and supporting engraftment in bone marrow transplantation. While, placental and umbilical cord-derived mesenchymal stem cells (PC-UC-MSCs) are obtained from the placenta and the umbilical cord following childbirth. These cells are non-invasive to collect and have a higher proliferation rate than adult stem cells, such as AD-MSCs and BM-MSCs.

Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas

Stem cells are being explored as a revolutionary option in the treatment of various cardiovascular diseases, including myocardial infarction and congestive heart failure. Procedures utilizing stem cells have the potential to regenerate damaged heart tissue, improve heart function, and stimulate the repair of cardiac cells. In diseases including lupus and rheumatoid arthritis, sclerosis stem cell therapy can modify the disease process and restore immune balance. These cells can modulate T-cell responses and have been used to treat certain autoimmune diseases. For conditions such as osteoarthritis, muscular dystrophy, and other musculoskeletal disorders, stem cell therapy is promising for regenerating cartilage, bone, and muscle tissues. The treatment aims to reduce pain, improve function, and possibly delay or avoid the need for more invasive treatments like joint replacements. Stem cell therapy's potential to treat neurological disorders such as Alzheimer's is its capacity to protect, repair, or replace neurons and glial cells. Stem cells demonstrate a significant capacity to enhance the healing of wounds and injuries. By deploying MSCs in wound care, these cells can promote the regeneration of skin tissue, reduce scarring, and improve healing times. This is particularly relevant for burn victims, patients with diabetic ulcers, or individuals who experience slow wound healing.

End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes

Academic & research centers are crucial in advancing stem cell science and require various stem cell types to propel disease study, medication development, and therapy innovation breakthroughs. These institutions significantly contribute to pioneering studies and serve as a breeding ground for innovation in stem cell applications. On the other hand, ambulatory surgical centers (ASCs) provide a setting for certain types of outpatient stem cell therapies. These centers, less resource-intensive than hospitals, offer a cost-effective alternative for patients and insurers. Hospitals and clinics remain the primary care setting for the administration of stem cell therapies, particularly for more complex and acute medical conditions. The diverse patient population they serve creates a need for a broad range of stem cell therapies, including hematopoietic stem cell transplantation (HSCT) for diseases such as leukemia and lymphoma and various regenerative medicine applications. Biopharmaceutical companies are key players in the development and commercialization of stem cell therapies. They not only purchase stem cells for R&D purposes - working on new drug discoveries and development of regenerative medicine - but also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale. Biopharma's interest in stem cell therapies corresponds with its ongoing search for innovative treatments that offer improved outcomes over existing medicines. Biopharmaceutical companies work on the development and commercialization of stem cell therapies. They purchase stem cells for R&D purposes to on new drug discoveries and the development of regenerative medicine and also for the purpose of manufacturing, where stem cell lines are used to produce therapeutic products at scale.

Regional Insights

In America, countries including the United States and Canada, advanced healthcare infrastructure and a high prevalence of chronic diseases have driven the need for innovative treatments such as stem cell therapy. The customer purchasing behavior reflects a greater propensity to adopt new healthcare technologies, particularly in areas such as regenerative medicine. Significant research investments and activity are evidenced by the region's major position in stem cell patents, which supports a robust and evolving therapy market. The European Union (EU) presents a diverse space for stem cell therapy, with countries including Germany, the UK, and France focusing on research and clinical applications. At the same time, the Middle East and Africa region is experiencing burgeoning interest in stem cell therapy with the huge investments in healthcare improvements and increased demand for advanced medical treatments. Initiatives such as the Dubai Cell Therapy and Regenerative Medicine Framework aim to position the region as a hub for medical tourism in stem cell therapy. Meanwhile, in Asia, countries such as China, Japan, and India reflect a rapidly expanding market for stem cell therapies, and the government's supportive policies have resulted in a flourishing environment for research and innovation. Japan's and China's progressive regulatory approach with the establishment of fast-track approval for regenerative medicine products has made these countries major spaces for stem cell therapy adoption. In India, growing healthcare infrastructure and increased public and private funding for research represent a shift towards greater usage and development of stem cell therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Stem Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stem Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., Aurion Biotechnologies, Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lineage Cell Therapeutics, Inc., Lonza Group AG, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, Sartorius CellGenix GmbH, SQZ Biotechnologies Company, Takara Bio Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Stem Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Allogeneic Stem Cell Therapy
    • Autologous Stem Cell Therapy
  • Cell Source
    • Adipose Tissue-Derived MSCs
    • Bone Marrow-Derived MSCs
    • Placental / Umbilical Cord-Derived MSCs
  • Therapeutic Application
    • Cardiovascular Diseases Surgeries
    • Inflammatory & Autoimmune Diseases
    • Musculoskeletal Disorders
    • Neurological Disorders
    • Orthopedics & Rheumatoid
    • Wounds & Injuries
  • End-User
    • Academic & Research Centers
    • Ambulatory Surgical Centers
    • Biotechnology & Pharmaceutical Companies
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Stem Cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stem Cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the Stem Cell Therapy Market?

4. What is the market share of the leading vendors in the Stem Cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the Stem Cell Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of degenerative diseases and cancer cases across the world
      • 5.1.1.2. Increasing government initiatives for stem cell therapy across the world
      • 5.1.1.3. Expansion of stem cell therapy centers and clinics
    • 5.1.2. Restraints
      • 5.1.2.1. Difficulties associated with performing stem cell therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in stem cell therapy
      • 5.1.3.2. Surging approvals for marketing and clinical trials for stem cell therapies and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and safety issues of stem cell-based therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing uses of allogeneic and autologous stem cell therapy in chronic disease treatments
    • 5.2.2. Cell Source: Rising adoption of AD-MSCs and BM-MSCs in tissue remodeling and tissue repairing
    • 5.2.3. Therapeutic Application: Growing popularity of regenerative medicine in varied therapeutics areas
    • 5.2.4. End-User: Increasing uses of stem cell therapy in academics & research centers and hospitals offering effective, safe, and standardized treatment outcomes
  • 5.3. Market Trend Analysis
    • 5.3.1. Rigorous stem cell therapy based research initiatives, evolving regulatory frameworks, and an increasing demand for advanced therapies is fueling market in Americas
    • 5.3.2. Advancements in stem cell therapies backed by government fundings and rising adoption due to medical tourism practices in the APAC countries
    • 5.3.3. Strong network of academic institutions and biotech firms backed by government funding to accelerate stem cell research and commercialization in EMEA
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Stem Cell Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Allogeneic Stem Cell Therapy
  • 6.3. Autologous Stem Cell Therapy

7. Stem Cell Therapy Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Adipose Tissue-Derived MSCs
  • 7.3. Bone Marrow-Derived MSCs
  • 7.4. Placental / Umbilical Cord-Derived MSCs

8. Stem Cell Therapy Market, by Therapeutic Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases Surgeries
  • 8.3. Inflammatory & Autoimmune Diseases
  • 8.4. Musculoskeletal Disorders
  • 8.5. Neurological Disorders
  • 8.6. Orthopedics & Rheumatoid
  • 8.7. Wounds & Injuries

9. Stem Cell Therapy Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Centers
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Biotechnology & Pharmaceutical Companies
  • 9.5. Hospitals & Clinics

10. Americas Stem Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Stem Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Stem Cell Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Fujifilm to Invest USD 200 Million in Cell Therapy Production
    • 13.3.2. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
    • 13.3.3. Selecta Biosciences Announces Merger with Cartesian Therapeutics
    • 13.3.4. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
    • 13.3.5. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
    • 13.3.6. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
    • 13.3.7. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
    • 13.3.8. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
    • 13.3.9. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
    • 13.3.10. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
    • 13.3.11. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
    • 13.3.12. Novo Nordisk to Expand R&D Presence in Greater Boston Area
    • 13.3.13. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 13.3.14. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
    • 13.3.15. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. STEM CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. STEM CELL THERAPY MARKET DYNAMICS
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BONE MARROW-DERIVED MSCS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BONE MARROW-DERIVED MSCS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL / UMBILICAL CORD-DERIVED MSCS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL / UMBILICAL CORD-DERIVED MSCS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES SURGERIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES SURGERIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ORTHOPEDICS & RHEUMATOID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ORTHOPEDICS & RHEUMATOID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY WOUNDS & INJURIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY WOUNDS & INJURIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 114. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. CHINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. CHINA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. INDIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. JAPAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. JAPAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. THAILAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. THAILAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. DENMARK STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 220. DENMARK STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. EGYPT STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 228. EGYPT STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. FINLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. FINLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. FRANCE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 244. FRANCE STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. GERMANY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. GERMANY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. ITALY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 268. ITALY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 291. NORWAY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 292. NORWAY STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. POLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 300. POLAND STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. QATAR STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 308. QATAR STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 315. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 316. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 324. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 332. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 337. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 338. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 339. SPAIN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 340. SPAIN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)
  • TABLE 345. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 346. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 347. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 348. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024-2030 (USD MILLION)